RESUMO
RESUMEN La leucemia viral felina (ViLeF) es una enfermedad retroviral letal, de una elevada prevalência en Colombia, que afecta a felinos de diferentes edades y sexos. El objetivo de esta investigación fue determinar la frecuencia por serodiagnóstico de ViLeF en felinos del centro integral de bienestar animal Ceiba, ubicado en Rionegro, Antioquia (Colombia), en 2020. Para ello, se realizó un estudio descriptivo longitudinal de serofrecuencia de ViLeF desde enero hasta diciembre de 2020. Fueron muestreados 92 gatos, a los cuales se les efectuó una prueba p27 por inmunoensayo comercial Elisa (Idexx©, Snap Combo Plus®, Maine, EE. UU.). La frecuencia de felinos positivos fue 30/92 (32,60%) y el mes de mayo fue el de mayor frecuencia (9,78%). Los machos positivos fueron 17/92 (18,47%) y las hembras 13/92 (14,13%). La edad promedio de seropositividad fue 2,14 años. La frecuencia de ViLeF en 2020 para Ceiba, Rionegro (Colombia) es de 32,60%, un valor elevado con respecto a descripciones en otros albergues para felinos. ViLeF es una enfermedad que está siendo reportada con mayor frecuencia en Colombia, debido a que las medidas de prevención no se están adoptando rutinariamente.
ABSTRACT Feline viral leukemia (ViLeF) is a lethal retroviral disease with a high prevalence in Colombia that affects felines of different ages and sexes. The purpose of this investigation was to determine the frequency by serodiagnosis of ViLeF in felines of the integral center of animal welfare Ceiba, located in Rionegro, Antioquia (Colombia), during 2020. For that, a longitudinal descriptive study of ViLeF serofrequency from were made January to December 2020. 92 cats were sampled, which were tested for p27 by commercial Elisa immunoassay (Idexx©, Snap Combo Plus®, Maine, USA). The frequency of positive felines was 30/92 (32,60%). May was the month with the highest frequency (9,78%). The positivity frequency for males was 17/92 (18,47%) and the frequency for females 13/92 (14,13%). The main age of seropositivity was 2,14 years. The frequency of ViLeF in 2020 for Ceiba, Rionegro (Colombia) is 32,60%. This is a high value in comparison to descriptions in other shelters for felines. ViLeF, in Colombia, is a disease that has been reported with more frequency because prevention measures are not being adopted routinely.
Assuntos
Animais , Gatos , Ensaio de Imunoadsorção Enzimática , Morbidade , Cromatografia de Afinidade , Leucemia Felina , Vírus da Leucemia Felina , Felidae , Imunoensaio , Testes Sorológicos , Doença , PrevalênciaRESUMO
Retinoblastoma (Rb) is a pediatric intraocular malignancy and probably the most robust clinical model on which genetic predisposition to develop cancer has been demonstrated. Since deletions in chromosome 13 have been described in this tumor, we performed next generation sequencing to test whether recurrent losses could be detected in low coverage data. We used Illumina platform for 13 tumor tissue samples: two pools of 4 retinoblastoma cases each and one pool of 5 medulloblastoma cases (raw data can be found at http://www.ebi.ac.uk/ena/data/view/PRJEB6630). We first created an in silico reference profile generated from a human sequenced genome (GRCh37p5). From this data we calculated an integrity score to get an overview of gains and losses in all chromosomes; we next analyzed each chromosome in windows of 40 kb length, calculating for each window the log2 ratio between reads from tumor pool and in silico reference. Finally we generated panoramic maps with all the windows whether lost or gained along each chromosome associated to its cytogenetic bands to facilitate interpretation. Expression microarrays was done for the same samples and a list of over and under expressed genes is presented here. For this detection a significance analysis was done and a log2 fold change was chosen as significant (raw data can be found at http://www.ncbi.nlm.nih.gov/geo/accession number GSE11488). The complete research article can be found at Cancer Genetics journal (Garcia-Chequer et al., in press) [1]. In summary here we provide an overview with visual graphics of gains and losses chromosome by chromosome in retinoblastoma and medulloblastoma, also the integrity score analysis and a list of genes with relevant expression associated. This material can be useful to researchers that may want to explore gains and losses in other malignant tumors with this approach or compare their data with retinoblastoma.
RESUMO
Genes are frequently lost or gained in malignant tumors and the analysis of these changes can be informative about the underlying tumor biology. Retinoblastoma is a pediatric intraocular malignancy, and since deletions in chromosome 13 have been described in this tumor, we performed genome wide sequencing with the Illumina platform to test whether recurrent losses could be detected in low coverage data from DNA pools of Rb cases. An in silico reference profile for each pool was created from the human genome sequence GRCh37p5; a chromosome integrity score and a graphics 40 Kb window analysis approach, allowed us to identify with high resolution previously reported non random recurrent losses in all chromosomes of these tumors. We also found a pattern of gains and losses associated to clear and dark cytogenetic bands respectively. We further analyze a pool of medulloblastoma and found a more stable genomic profile and previously reported losses in this tumor. This approach facilitates identification of recurrent deletions from many patients that may be biological relevant for tumor development.